Advancements in risk stratification and management strategies in primary cardiovascular prevention
- PMID: 38824844
- DOI: 10.1016/j.atherosclerosis.2024.117579
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for advancements in risk assessment and management strategies. Although significant progress has been made recently, identifying and managing apparently healthy individuals at a higher risk of developing atherosclerosis and those with subclinical atherosclerosis still poses significant challenges. Traditional risk assessment tools have limitations in accurately predicting future events and fail to encompass the complexity of the atherosclerosis trajectory. In this review, we describe novel approaches in biomarkers, genetics, advanced imaging techniques, and artificial intelligence that have emerged to address this gap. Moreover, polygenic risk scores and imaging modalities such as coronary artery calcium scoring, and coronary computed tomography angiography offer promising avenues for enhancing primary cardiovascular risk stratification and personalised intervention strategies. On the other hand, interventions aiming against atherosclerosis development or promoting plaque regression have gained attention in primary ASCVD prevention. Therefore, the potential role of drugs like statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, omega-3 fatty acids, antihypertensive agents, as well as glucose-lowering and anti-inflammatory drugs are also discussed. Since findings regarding the efficacy of these interventions vary, further research is still required to elucidate their mechanisms of action, optimize treatment regimens, and determine their long-term effects on ASCVD outcomes. In conclusion, advancements in strategies addressing atherosclerosis prevention and plaque regression present promising avenues for enhancing primary ASCVD prevention through personalised approaches tailored to individual risk profiles. Nevertheless, ongoing research efforts are imperative to refine these strategies further and maximise their effectiveness in safeguarding cardiovascular health.
Keywords: Atherosclerosis; Cardiovascular disease; Plaque regression; Primary prevention; Risk stratification.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest F.B. has received honoraria and grants from Novartis, Novo Nordisk, Sanofi, and Viatris, outside the scope of the submitted work. All other authors declare to have no conflict of interest.
Similar articles
-
Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents.Clin Ther. 2023 Nov;45(11):1127-1136. doi: 10.1016/j.clinthera.2023.08.021. Epub 2023 Sep 26. Clin Ther. 2023. PMID: 37770308 Review.
-
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019 Jun 18;139(25):e1144-e1161. doi: 10.1161/CIR.0000000000000626. Epub 2018 Nov 10. Circulation. 2019. PMID: 30586775
-
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases.Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):758-769. doi: 10.1093/ehjcvp/pvad059. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 37562936
-
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol. 2019 Jun 25;73(24):3210-3227. doi: 10.1016/j.jacc.2018.11.004. Epub 2018 Nov 10. J Am Coll Cardiol. 2019. PMID: 30423394
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.
Cited by
-
Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.J Clin Med. 2025 Apr 16;14(8):2750. doi: 10.3390/jcm14082750. J Clin Med. 2025. PMID: 40283580 Free PMC article. Review.
-
Advancements in the Treatment of Atherosclerosis: From Conventional Therapies to Cutting-Edge Innovations.ACS Pharmacol Transl Sci. 2024 Dec 4;7(12):3804-3826. doi: 10.1021/acsptsci.4c00574. eCollection 2024 Dec 13. ACS Pharmacol Transl Sci. 2024. PMID: 39698263 Review.
-
Irregular Pulse and Cardiovascular Disease From NHANES (1999-2018): A Cross-Sectional Study.Health Sci Rep. 2025 Jan 23;8(1):e70349. doi: 10.1002/hsr2.70349. eCollection 2025 Jan. Health Sci Rep. 2025. PMID: 39867712 Free PMC article.
-
The association between the visceral to subcutaneous abdominal fat ratio and the risk of cardiovascular diseases: a systematic review.BMC Public Health. 2024 Jul 9;24(1):1827. doi: 10.1186/s12889-024-19358-0. BMC Public Health. 2024. PMID: 38982435 Free PMC article.
-
Charting the Unseen: How Non-Invasive Imaging Could Redefine Cardiovascular Prevention.J Cardiovasc Dev Dis. 2024 Aug 9;11(8):245. doi: 10.3390/jcdd11080245. J Cardiovasc Dev Dis. 2024. PMID: 39195153 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous